Clinical Trials
47 trialsN2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation
New Approaches to Neuroblastoma Therapy Consortium
N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol
Children's Hospital of Philadelphia
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Memorial Sloan Kettering Cancer Center
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Children's Oncology Group
MIBG for Refractory Neuroblastoma and Pheochromocytoma
Masonic Cancer Center, University of Minnesota
NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab
New Approaches to Neuroblastoma Therapy Consortium
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
University of California, San Francisco
MIBG
Nationwide Children's Hospital
MIBG With Dinutuximab +/- Vorinostat
New Approaches to Neuroblastoma Therapy Consortium
Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors
University of Michigan Rogel Cancer Center
131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma
University of Texas Southwestern Medical Center
A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma
Northwell Health
SPORE-3
University of Iowa
Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Children's Hospital Medical Center, Cincinnati
Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
University of Iowa
N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Expanded Access Protocol Using 131I-MIBG
Jubilant DraxImage Inc.
OPTIMUM
Jubilant DraxImage Inc.
N2011-01
New Approaches to Neuroblastoma Therapy Consortium
MIBNET
AC Camargo Cancer Center
124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study
University of California, San Francisco
Haploidentical Stem Cell Transplantation in Neuroblastoma
Lund University Hospital
Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
University of California, San Francisco
A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma
GE Healthcare
High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma
University of California, San Francisco
Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors
M.D. Anderson Cancer Center
A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
University of California, San Francisco
131MIBG to Treat Malignant Pheochromocytoma
National Institutes of Health Clinical Center (CC)
MIITOP
Centre Oscar Lambret
Combination Targeted Radiotherapy in Neuroendocrine Tumors
University of Iowa
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
Response-based Treatment of High-risk Neuroblastoma
Samsung Medical Center
VIBRaNT
University College, London
Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma
National Cancer Institute (NCI)
131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma
University of California, San Francisco
Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma
National Cancer Institute (NCI)
High-Dose Iodine I 131 Metaiodobenzylguanidine, Topotecan, and Peripheral Stem Cell Transplant in Treating Young Patients With Relapsed Stage 4 Neuroblastoma or Primary Resistant High-Risk Neuroblastoma
National Cancer Institute (NCI)
131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma
Tehran University of Medical Sciences
N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma
GE Healthcare
CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study
National Center for Research Resources (NCRR)